RxDoctor Payments Data

Guillaume Lamotte, MD

Neurology · Rochester, MNNPI 1114371416

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,200 of the $3,604 with a category attached, or 88.8%. Lundbeck LLC accounts for 88.8% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $3,200, more than ten times the $21 reported in 2019.

$3,604in general payments, 2019–2025

Across 7 payments — averaging $514.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$3K
  • Acadia Pharmaceuticals Inc$143
  • Merz North America, Inc.$133
  • Amneal Pharmaceuticals LLC$111
  • AbbVie$17
$106,021in research payments, 2019–2025

Across 23 payments — averaging $4609.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$106K

What the payments were for

  • Speaking & faculty fees$3,20089%
  • Food & beverage$40411%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,604 in reported general payments places this provider in the 80th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$75,449
Medicare patients
242
Services billed
939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa16$65,902
Carbidopa-LevodopaCarbidopa/Levodopa437$20,851
Droxidopa27$13,612
Carbidopa-Levodopa ErCarbidopa/Levodopa126$6,705
Midodrine Hcl65$5,159
Rivastigmine18$3,714
Pyridostigmine Bromide64$3,448
Entacapone19$2,862
Gabapentin86$2,210
AmantadineAmantadine Hcl52$2,187
Rasagiline Mesylate20$1,772
Ropinirole Hcl30$1,327
Donepezil Hcl96$1,289
Pramipexole ErPramipexole Di-Hcl12$1,201
Propranolol Hcl ErPropranolol Hcl19$985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$111$69,35080 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 neurology providers in Minnesota.

Other neurology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →